SYN-818: An Investigational DNA Polymerase Theta (Polθ) Inhibitor for Precision Oncology

I. Introduction to SYN-818

A. Overview of SYN-818

SYN-818 is an orally available, investigational novel small molecule inhibitor specifically designed to target DNA Polymerase Theta (Polθ).[1] Its development is centered on the principles of precision oncology, aiming to exploit vulnerabilities within the DNA damage repair (DDR) mechanisms of cancer cells.[1] A core concept underpinning its therapeutic strategy is synthetic lethality, particularly in tumors characterized by deficiencies in homologous recombination (HR) repair pathways, such as those with BRCA1 or BRCA2 mutations.[1]

B. Developer: SynRx Therapeutics

SYN-818 is an asset independently developed by SynRx Therapeutics Co., Ltd..[1] Founded in 2021 and headquartered in Hangzhou, China, SynRx Therapeutics is a biopharmaceutical company specializing in precision oncology, with a particular focus on DDR pathways and synthetic lethality.[1] The company successfully secured $14.2 million in seed funding to support its research and development endeavors.[6] SYN-818 represents a significant milestone for the company, being its first internally developed innovative drug candidate to progress into the clinical development stage.[1]